SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist.

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.91.17.8052
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Rationally Designed Polycationic Carriers for Potent Polymeric siRNA-Mediated Gene Silencing

ACS Nano
Materials ScienceNanoscienceEngineeringNanotechnologyAstronomyPhysics
2018English

Potent Anti-Inflammatory and Antinociceptive Activity of the Endothelin Receptor Antagonist Bosentan in Monoarthritic Mice

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2011English

Rationally Designed Tularemia Vaccines

Expert Review of Vaccines
Molecular MedicineDrug DiscoveryImmunologyPharmacology
2009English

Delaminomycins, Novel Nonpeptide Extracellular Matrix Receptor Antagonist and a New Class of Potent Immunomodulator. I. Taxonomy, Fermentation, Isolation and Biological Activity.

Journal of Antibiotics
Drug DiscoveryPharmacology
1993English

Metabolism-Based Identification of a Potent Thrombin Receptor Antagonist

English

Effects of WIN 64338, a Nonpeptide Bradykinin B2 Receptor Antagonist, on Guinea-Pig Trachea

British Journal of Pharmacology
Pharmacology
1995English

The Effects of an Endothelin-A Receptor Antagonist on Choroidal Circulation

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
1997English

A Novel Nonpeptide CGRP Receptor Antagonist, ‘Compound 1’ (WO98/11128) Is a High Affinity Competitive Antagonist at the CGRP1 Receptor in Human Coronary Arteries

The Scientific World Journal
BiochemistryMedicineGeneticsMolecular BiologyEnvironmental Science
2001English

Rationally Designed Complex, Hierarchical Microarchitectures

Science
MultidisciplinaryPhilosophy of ScienceHistory
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy